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Abstract   
 
Objectives: The role of clinical pharmacists in hospitals has evolved and continues to expand. 
In the UK, outside a few national policy drivers, there are no agreed priorities, measures or 
defined outcomes for hospital clinical pharmacy (CP). This paper aims to 1) highlight the need 
to identify and prioritise specific clinical pharmacy roles, responsibilities and practices that will 
bring the greatest benefit to patients and health-systems and 2) describe systemic 
weaknesses in current research methodologies for evaluating clinical pharmacy services and 
propose a different approach 
Method: Published reviews of CP services are discussed using the economic, clinical and 
humanistic outcomes (ECHO) framework. Recurring themes regarding study methodologies, 
measurements and outcomes are used to highlight current weaknesses in studies evaluating 
CP. 
Results: Published studies aiming to demonstrate the economic, clinical or humanistic 
outcomes of clinical pharmacy often suffer from poor research design and inconsistencies in 
interventions, measurements and outcomes. This has caused difficulties in drawing 
meaningful conclusions regarding clinical pharmacy’s definitive contribution to patient 
outcomes.  
Conclusion: There is a need for more research work in NHS hospitals, employing a different 
paradigm to address some of the weaknesses of existing research on clinical pharmacy 
practice.  We propose a mixed-methods approach, including qualitative research designs, and 
with emphasis on cost-consequence analyses for economic evaluations. This approach will 
provide more meaningful data to inform policy and demonstrate the contribution of hospital 
clinical pharmacy activities to patient care and the NHS.   
  
4 
Key Messages 
What is already known on this subject  
• Clinical Pharmacy is a diverse, complex discipline and clinical pharmacy activities are 
not easily defined or described 
• It is important to robustly show the benefits of clinical pharmacy, in order to justify 
resource use and to prioritise and measure activities 
• Studies purporting to demonstrate the outcomes of clinical pharmacy activities are 
often criticized due to methodological flaws, poor intervention descriptions and weak 
conclusions 
 
What this study adds  
• The current positivist mindset is weakening the case for clinical pharmacy. There is a 
need for a new research approach for studying and evaluating clinical pharmacy 
interventions 
• Mixed-methods studies, incorporating quantitative and qualitative methodologies are 
more appropriate for evaluating the outcomes of clinical pharmacy 
• Cost-consequence analyses are more suitable for evaluating the economic outcomes 
of clinical pharmacy 
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Introduction 
Clinical pharmacy (CP) is a relatively new healthcare discipline, compared to professions such 
as medicine and nursing.  Traditionally, pharmacists were solely concerned with procurement, 
dispensing, manufacturing and supply of drugs[1]. The official development of CP in the UK 
began in 1970, with the publication of the government-commissioned ‘Noel Hall Report’[2].  
Since then, several influential policy documents have been published which have contributed 
to the development of CP in the UK (see supplementary information). This has led to CP being 
advocated as vital to the optimal and safe care of patients[3].  Notably, the development of CP 
in mainland Europe is more variable although expanding [4–6].  Despite the widespread 
support for CP in hospitals however, there is no agreement within the profession on which 
components of practice are most important.  Moreover, research into the outcomes of CP has 
not kept pace with the developments in practice.  
 
The UK National Health Service (NHS) is under severe financial pressure, a situation which is 
likely to remain for the foreseeable future [7]. Medicines remain the most common therapeutic 
intervention offered to patients and their costs are significant. The NHS spends £6.7 billion on 
hospital medicines annually[8]. Most NHS trusts spend between 5 and 10% of their total costs  
on drugs[8] and medicines expenditure increases by an average of 15% every year[9]. 
Significant resources are invested by trusts to secure their CP workforce. Annually, £0.6 billion 
is spent on hospital pharmacy services and in 2015/16 pay costs of hospital pharmacists alone 
averaged nearly £300,000 per 100 beds[10]. It is therefore important that these resources are 
deployed such that they give greatest benefits.  
 
This paper explores the complexities of hospital clinical pharmacy practice and the consequent 
difficulties producing robust research evidence on the effectiveness of clinical pharmacy.  The 
aim is to evaluate and highlight the quality of evidence and to suggest an alternative approach 
for researcher-practitioners. 
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 The evolving role of clinical pharmacists 
The complexity of clinical pharmacy practice is reflected in the fact that various definitions 
have been proposed. In the literature, the terms clinical pharmacy ‘services’, ‘activities’ and 
‘interventions’ are used interchangeably[11]. The difficulties in agreeing a single definition 
of clinical pharmacy relate to the diverse nature of the discipline. This is problematic for 
researchers and impedes the development of a coherent vision.   
 
Clinical pharmacy is concerned with both medicines policy and the treatment of patients, 
with the aim of achieving optimal use of medicines[11,12]. Additional aspects of CP, as 
advocated by The European Society of Clinical Pharmacy (ESCP), the Societe Francaise 
de Pharmacie Clinique (SFPC) and the United Kingdom Clinical Pharmacy Association 
(UKCPA) are concerned with attributes of the pharmacist that allow ‘the appropriate, 
effective and safe use of medicines’[13]. The role of clinical pharmacy has also expanded 
to include pharmaceutical care – providing drug therapy to achieve “definite outcomes that 
improve a patient’s quality of life” [14]. Medicines optimisation is a more recent, overarching 
concept that considers both clinical pharmacy activities and pharmaceutical care[15].  
 
Hospital clinical pharmacists interact with patients on wards, on multi-professional ward 
rounds or in clinic settings to treat, monitor and advise on the use of medicines. However, 
clinical pharmacy clearly encompasses more than just direct patient care. Therefore, 
activities such as production of guidelines and policies, advising on drug expenditure 
controls, training and education of other healthcare professionals are also included. The 
relationships between clinical pharmacy, pharmaceutical care and medicines optimisation 
are represented in Figure 1 and a list of typical CP activities is provided in Box 1.  
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Figure 1 here 
 
Box 1 here 
 
 
Figure 1.  The relationship between clinical pharmacy, pharmaceutical care, and medicines 
optimisation 
 
Box 1. Examples of typical hospital clinical pharmacy activities 
Medicines reconciliation - Steps taken to verify that a patient’s list of medication is not unintentionally changed 
when the patient moves from one care setting to another 
Prescription monitoring/Prescription review - Checking patients’ prescriptions for appropriateness or mistakes 
and then making recommendations to doctors 
Prescribing advice - Helping prescribers to choose the right medicines, doses, administration method etc. for 
individual patients  
Dose adjustments - Changing the dose of a drug to make it more appropriate for the patient 
Pharmacokinetic and therapeutic drug level consultations - For drugs which have a narrow gap between 
therapeutic and toxic doses, advising on blood level sampling and interpreting the results 
Medication administration advice - Advising nursing staff on the best way to administer a medicine, or choosing 
the correct form of the medicine to administer against a prescription 
Disease or drug-specific outpatient clinic services - E.g. participating in or leading respiratory, diabetes, 
hypertension or high-risk drug clinics to optimise treatment and prevent adverse effects  
Patient education and patient consultations - Advising and educating individuals or groups of patients to help 
them understand their medicines and adhere to the treatment plan that they have agreed to 
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Medication error reporting and resolution - Reporting medication errors to support organizational learning from 
mistakes and to prevent errors from being repeated 
Adverse drug reaction reporting - Reporting avoidable or unavoidable reactions to drugs 
Antimicrobial stewardship - Implementing and monitoring policies and systems for promoting and monitoring 
appropriate use of antimicrobial drugs  
Medication safety leadership and initiatives 
Training and education of other healthcare staff 
Managing formularies and the entry of new drugs 
Guideline and protocol writing 
Clinical audit 
Advising on or managing the medicines budget 
Ensuring the appropriate, safe and secure handling of medicines within the hospital (sometimes called medicines 
management) 
Source: Stephens M. Hospital Pharmacy, 2011[16] 
This table demonstrates the span and complexity of clinical pharmacy services. The list is not 
exhaustive, however represents more than 50% of typical workload. Clinical pharmacy 
services are not only delivered by pharmacists.  An overview of changing roles in the 
pharmacy workforce describes how pharmacy technicians have increasingly important clinical 
responsibilities for patient care, including medication history taking,  prescription checking and 
supporting patient adherence[17]. 
 
Levels of clinical pharmacy service provision are not consistent between hospitals. The 
most recent policy report concerning hospital CP in the UK was published in January 
2016[9]. This report decries the significant variation in the scope of CP activities between 
hospitals but also recommends that hospitals deploy 80% of their pharmacist resource 
towards direct patient care and medicines optimisation. In these financially constrained 
times, this will only be a good use of resource if one knows where benefits are most likely 
to be seen, and how to measure them. It is therefore essential that services are prioritised, 
and that this prioritisation is underpinned by appropriate evidence.  
9 
 
Current evidence on the outcomes and benefits of clinical pharmacy 
There are few agreed priorities and measures for hospital clinical pharmacy or its core ‘patient-
facing’ medicines optimisation activities. Common policy- or finance-driven activities are few, 
and include medicines reconciliation, antimicrobial stewardship, medication safety and general 
‘medicines management’. The Royal Pharmaceutical Society (RPS) published the first 
Professional Standards for Hospital Pharmacy Services for Great Britain in 2012 (refreshed in 
2014)[18]. There are ten overarching standards, and they provide hospital pharmacy 
departments with structure and guidance regarding expected services and responsibilities.  
Similar to the RPS standards, in 2014 the European Association of Hospital Pharmacists 
(EAHP) developed 44 European Statements for Hospital Pharmacy services. The statements 
articulate objectives for the delivery of hospital pharmacy services in European health systems  
[19]. However, the nature of both the RPS Standards and the EAHP Statements is such that 
they offer little help with prioritising services to be developed (or indeed services to disinvest 
from); they are also not measurable indicators.   Extracts from the standards and statements 
documented can be seen in Box 2. 
 
 Box 2.  Extracts from the Royal Pharmaceutical Society Professional Standards for 
Hospital Pharmacy Standards[18] and European Association of Hospital Pharmacy 
Statements for Hospital Pharmacy Services [19] 
RPS Standard 2 Episode of Care  
Patients’ medicines requirements are regularly assessed and responded to, in order to keep them safe and optimise 
their outcomes from medicines. 
2.1 On admission or at first contact  
Patients’ medicines are reviewed to ensure an accurate medication history, for clinical appropriateness and to identify 
patients in need of further pharmacy support. 
a. The pharmacy team provides the leadership, systems support and expertise that enables a multidisciplinary team 
to: 
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- Reconcile patients’ medicines as soon as possible, ideally within 24 hours of hospital admission to avoid 
unintentional changes to medication 
- Effectively document patients’ medication histories as part of the admission process 
- Give patients access to the medicines that they need from the time that their next dose is needed  
- Identify patients in need of pharmacy support and pharmaceutical care planning  
- Identify potential medicines problems affecting discharge (or transfer to another care setting) so that they can be 
accommodated to avoid extending patients’ stays in hospital. 
 
2.2 Care as an inpatient 
Patients have their medicines reviewed by a clinical pharmacist to ensure that their medicines are clinically 
appropriate, and to optimise their outcomes from their medicines. 
a. Pharmacists regularly clinically review patients and their prescriptions to optimise outcomes from medicines (timing 
and level of reviews adjusted according to patient need and should include newly prescribed medicines out of hours) 
and take steps to minimise omitted and delayed medicine doses in hospitals. 
b. Patients targeted for clinical pharmacy support have their medicines’ needs assessed and documented in a care 
plan that forms part of the patient record. 
c. Pharmacists attend relevant multidisciplinary ward rounds, case reviews and/or clinics. 
d. Patients, medical and nursing teams have access to pharmacy expertise when needed.  
e. The pharmacy team provides the leadership, systems support and expertise that enables patients to: 
- Bring their own medicines into hospital with them and self-administer one or more of these wherever possible 
- Have their own medicines returned at discharge where appropriate. 
EAHP Statements Section 4: Clinical Pharmacy Standards 
4.1 Hospital pharmacists should be involved in all patient care settings to prospectively influence collaborative, 
multidisciplinary therapeutic decision-making; they should play a full part in decision making including advising, 
implementing and monitoring medication changes in full partnership with patients, carers and other health care 
professionals. 
 
4.2 All prescriptions should be reviewed and validated as soon as possible by a hospital pharmacist. Whenever the 
clinical situation allows, this review should take place prior to the supply and administration of medicines. 
 
4.3 Hospital pharmacists should have access to the patients’ health record. Their clinical interventions should be 
documented in the patients’ health record and analysed to inform quality improvement interventions. 
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4.4 All the medicines used by patients should be entered on the patient’s medical record and reconciled by the 
hospital pharmacist on admission. Hospital pharmacists should assess the appropriateness of all patients’ medicines, 
including herbal and dietary supplements. 
 
4.5 Hospital pharmacists should promote seamless care by contributing to transfer of information about medicines 
whenever patients move between and within healthcare settings. 
 
4.6 Hospital pharmacists, as an integral part of all patient care teams, should ensure that patients and carers are 
offered information about their clinical management options, and especially about the use of their medicines, in terms 
they can understand. 
 
4.7 Hospital pharmacists should inform, educate and advise patients, carers and other health care professionals 
when medicines are used outside of their marketing authorisation. 
 
4.8 Clinical pharmacy services should continuously evolve to optimise patients’ outcomes. 
 
Researchers have highlighted the paucity of robust research regarding the impact of CP 
services on organisational and patient outcomes, as well as the lack of information to support 
the most efficient use of available resources [20–23]. A review of the impact of clinical 
pharmacy services on health-related quality of life found that methodologies had improved, but 
studies often did not include a control group[20]. Perez et al.[21] advocate improvements in 
the design of CP economic evaluation studies. The authors explain how relatively minor 
changes would improve study rigour. Broad and unclear monitoring targets lead to 
inconclusive evidence in the evaluation of the impact of CP services. More conclusive 
evidence for the effectiveness of clinical pharmacy services are reported when the 
interventions are rigorously defined, in specific medical conditions, and when there are 
unequivocal outcomes[24].  Often, pharmacists are sole practitioners when providing specialist 
services which makes unpicking and measuring their individual clinical contributions relatively 
straightforward.  However, most hospital clinical pharmacists work in multidisciplinary teams 
where linking patient outcomes and pharmacy input is difficult to achieve. This lack of outcome 
measurement leads to lack of evidence, thus perpetuating the status quo. Clearly, identifying 
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criteria for measuring clinical pharmacy services should be an important aim.  Some 
researchers have attempted to develop performance indicators[25,26].  An issue still to be 
overcome is that the indicators for hospital clinical pharmacy found in the literature are all 
process-based; they measure inputs, rather than outcomes. Fernandes and colleagues[27] 
published a Canadian consensus list of eight Key Clinical Pharmacy Key Performance 
Indicators (cpKPIs) with evidence supporting an impact on patient outcomes with a direct link 
to patient care. This work represents the most systematic approach so far towards the 
development of Key Performance Indicators.  The available evidence on the outcomes and 
impact of hospital clinical pharmacy services therefore still merits exploration.  
 
The ECHO model 
The framework for assessing Economic, Clinical and Humanistic Outcomes (ECHO)[28] is a 
useful tool for framing the impacts of CP.  Using the ECHO model (as described below and in 
Table 1), we illustrate the challenges with measuring outcomes of CP.  The approach used is 
a narrative overview of reviews of CP services published in the international literature.  To 
provide a complementary context, where there is a relatable EAHP Statement[17], we include 
this in the discussion.  
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Table 1. Summaries and critical evaluations of studies of Economic, Clinical and Humanistic Outcomes (ECHOs) of clinical pharmacy 
services 
Outcomes 
evaluated 
Title and year of article No. of studies (set 
in UK hospitals) 
Summary of findings Reported limitations of included studies 
Economic  
Economic effects of clinical pharmacy 
interventions: a literature review[29] 
(2008) 
21 (0) Cost–benefit analyses suggested that general 
clinical pharmacy interventions are associated 
with cost savings.  
Absence of control groups, limited scope of 
costs and outcomes, exclusion of costs of 
providing the service and absence of 
incremental cost analyses or benefit: cost 
ratios. 
Economic Evaluations of Clinical 
Pharmacy Services: 2006–2010[30] 
(2014) 
25 (1) CP services were generally considered cost-
effective or provided a good benefit-cost ratio.  
Variability in clinical outcomes contributed to 
variations in the cost-effectiveness findings. 
Future studies should focus on identifying 
specific aspects of CP services that contribute 
to improved clinical outcomes and efficiency. 
Economic evaluations of clinical 
pharmacist interventions on hospital 
inpatients: a systematic review of 
recent literature[31] (2014) 
22 (0) Overall, pharmacist interventions had a positive 
impact on hospital budgets and continue to 
provide cost-savings.  
Impossible to determine which interventions 
were most beneficial because interventions 
and outcome measures were so disparate. 
Economic & 
Clinical  
The economics of medicines 
optimization: policy developments, 
remaining challenges and research 
priorities[32] (2014) 
107 (0) There was a large evidence base on the 
effectiveness of interventions to improve the 
suboptimal use of medicines; the cost-
effectiveness evidence is much smaller.  
The available evidence is insufficient to assess 
the effectiveness and cost-effectiveness of 
medicines optimisation interventions. 
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Outcomes 
evaluated 
Title and year of article No. of studies (set 
in UK hospitals) 
Summary of findings Reported limitations of included studies 
Economic 
and 
Humanistic 
Humanistic and economic outcomes of 
pharmacist-provided medication review 
in the community-dwelling elderly: A 
systematic review and meta-analysis 
[33] (2016) 
25 (0) The findings suggest that the humanistic and 
economic outcomes of pharmacist-provided 
medication review are similar to those of usual 
care. 
All studies had a high to medium risk of bias. 
Components of generic HRQoL measures may 
not be significantly influenced by medication 
review. There was a failure to differentiate 
between necessary spending and undesirable 
spending. In many studies, follow-up may not 
have been long enough to detect changes in 
outcomes 
Economic, 
Clinical & 
Humanistic 
Economic effects of pharmacists on 
health outcomes in the United States: 
A systematic review[34] (2010) 
126 (0) Twenty studies showed results favouring 
pharmacist-provided care. Reduced length of stay 
and drug costs were seen for inpatients when 
pharmacists managed specific drug therapies; 
varied results for humanistic outcomes.  
Partial cost analyses, focus on drug costs and 
not cost of service, poor design and other 
flaws limited the majority of studies. 
Medication reviews by clinical 
pharmacists at hospitals lead to 
improved patient outcomes: a 
systematic review[35](2013) 
31 (1) A positive effect on medication use and costs, 
quality of prescribing, satisfaction with the service 
and both positive and insignificant effects on 
health service use were seen in some studies. 
The majority of the included studies used weak 
methodologies. 
The role of the pharmacist in 
optimizing pharmacotherapy in older 
people[36] (2012) 
16 RCTs (2 
RCTs), 9 
systematic 
reviews 
 
Proactive action of pharmacists improved 
pharmacotherapy for older patients. Mixed 
evidence on the impact of pharmacists’ 
interventions on health outcomes, quality of life or 
cost effectiveness of care.  
Single-centre studies, limited generalisability, 
contamination bias. Economic analyses are 
needed. 
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Outcomes 
evaluated 
Title and year of article No. of studies (set 
in UK hospitals) 
Summary of findings Reported limitations of included studies 
Clinical & 
Humanistic 
Does pharmacist‐led medication 
review help to reduce hospital 
admissions and deaths in older 
people? A systematic review and 
meta‐analysis[37] (2008) 
32 (3) Possible weak effects on knowledge, adherence 
and reductions in number of drugs prescribed.  
Insufficient data to know whether quality of life is 
improved. No effect on reducing mortality or 
hospital admission. 
Heterogeneity of studies.  Inconsistent 
reporting of outcomes. Some of the studies 
may have been susceptible to bias. 
Clinical 
Clinical Pharmacists and Inpatient 
Medical Care: A Systematic 
Review[38] (2006) 
36 (0) The addition of clinical pharmacist services in the 
care of inpatients generally resulted in improved 
care, with no evidence of harm.  
Small sample sizes, single institution and 
limited generalisability. 
Medication review in hospitalised 
patients to reduce morbidity and 
mortality[39] (2013) 
5 (0) No effect on mortality or readmissions. There was 
a reduction in ED contacts. Medication review 
should not be undertaken outside the context of 
robust trials with long follow-up.   
In three of the studies, either a physician or 
clinical pharmacologist was also involved in 
the actual reviews, and any unique contribution 
of the clinical pharmacist could not be 
assessed. 
The effect of early in‐hospital 
medication review on health outcomes: 
a systematic reviews[40] (2015) 
7 (0) No effect on length of hospital stay, mortality or 
readmissions. A pooled effect on ED revisits failed 
to reach statistical significance.  
Methodologically flawed, with a high risk of 
selection bias. Wide variations in the 
interventions studied and missing data. 
Pharmacist-led interventions to reduce 
unplanned admissions for older 
people: a systematic review and meta-
analysis of randomised controlled 
trials[41] (2014) 
20 (3) Unplanned admissions not affected by hospital or 
community pharmacist interventions.  An effect 
was found with older people with heart failure, but 
further confirmation is needed due to 
heterogeneity.  
Moderate to high risk of bias. 
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Outcomes 
evaluated 
Title and year of article No. of studies (set 
in UK hospitals) 
Summary of findings Reported limitations of included studies 
Humanistic 
An update on evidence of clinical 
pharmacy services’ impact on health-
related quality of life[20] (2006) 
36 (2) Limited evidence of the impact of a few CP 
interventions on short-term HRQoL. 
Compared with studies published prior to 
1999, studies had improved: longer length of 
follow-up, a wider breadth of clinical services 
were evaluated and several studies were well 
designed and methodologically rigorous. 
RCT = Randomised Controlled Trial, CP = Clinical Pharmacy, ED = Emergency Department, HRQoL = Health-Related Quality of Life
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Economic outcomes: EAHP Statement 2.3 refers to the economic outcomes of CP, with 
reference to the requirement for hospital pharmacists to co-ordinate medicines formularies, 
linked to evidence on patient outcomes and pharmacoeconomic evaluations.  The American 
College of Clinical Pharmacy has commissioned reviews of economic evaluations of CP 
services since 1988. In the latest article in this series, published in 2014[30],  the authors 
found that benefit to cost (B:C) or Incremental Cost-Effectiveness Ratios (ICERs) were 
reported or could be calculated for just eight studies. The authors also reported that the quality 
of studies and the pharmacoeconomic evaluations had improved since their previous review, 
published in 2008. However, significant methodological weaknesses were still identified. In the 
most recent systematic review of economic evaluations of inpatient clinical pharmacist 
interventions, Gallagher and colleagues[31] found no studies from the UK.  Interventions 
examined included antimicrobial management, medicines optimisation, specialist input into 
areas such as neurosurgery and intensive care, and multi-dimensional services. All of these 
are hospital CP services currently provided in the UK. Three studies were assessed as ‘good’ 
quality, while seven were judged to be of poor quality.  Only one paper[42] included all criteria 
for an appropriate economic evaluation according to the Consolidated Health Economic 
Evaluation Reporting Standards[43] criteria.  Interestingly, this study[42] found that the in-
hospital clinical pharmacist service was probably not cost-effective. Elliot et al.[44] provide a 
comprehensive critique of the methodological quality of 31 cost-effectiveness studies of 
pharmacist interventions.  Twelve of the studies were from the UK, with just two based in 
hospitals. Overall, they found a range of factors contributing to the general lack of consensus 
about the effectiveness of pharmacy services.  The main ones were poor study design and 
data analysis, as well as variations in intervention design and delivery, resource use, 
measurement and outcomes[44].  
 
Clinical outcomes: Many of the objectives included in EAHP Statement 4 – Clinical Pharmacy 
Services - are applicable to ensuring appropriate clinical outcomes of CP. Specifically, 
statements 4.1, 4.2, 4.4, 4.6 and 4.8 refer to influencing therapeutic decisions, prescription and 
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medication review, medicines reconciliation, provision of appropriate information and 
optimising outcomes. Kaboli et al. [38] found that clinical pharmacists practising in the inpatient 
setting improved the quality, safety and efficiency of care. They also suggested that more 
research is needed to better understand the role of clinical pharmacists and the clinical areas 
most likely to benefit. They pointed out the limitations of the reviewed studies (small sample 
sizes, single institution and limited generalisability). Medication review is an area of practice 
that is common, to a greater or lesser degree, to all UK hospital CP services. It is described in 
the literature as a systematic and structured assessment of the drug treatment of an individual 
patient, with the aims of optimising the quality, safety and appropriate use of their medicines 
and reducing medication-related problems, either by a recommendation or by a direct change. 
It may or may not include a discussion with the patient[37,45].  Holland et al. [37] in their 
systematic review and meta-analysis of randomised controlled trials (RCTs) to assess the 
effects of medication reviews for older people, only found possible weak effects on patients’ 
knowledge and adherence and reductions in number of drugs prescribed. A Cochrane Review 
of medication reviews[39] found a reduction in emergency department contacts but no effect 
on mortality or readmissions. The authors concluded that medication review should not be 
undertaken outside the context of high quality trials with long follow up. Graabaek and 
Kjeldsen conducted a systematic mini-review of 31 hospital-based studies[35]. They describe 
positive effects of medication reviews on medication use and satisfaction with the service, but 
also comment on the weak methodologies of the included studies. Many of the aims of 
medicines optimisation mirror those of medication reviews. Faria et al.[32] reviewed the 
evidence on the effectiveness of medicines optimisation.  They concluded that more research 
on outcomes and which pharmacist duties are most beneficial to patients is needed.  Hohl et 
al.[40] looked at early in-hospital medication reviews by pharmacists. Given the weaknesses in 
the reviewed studies, the authors recommended high quality randomised trials to fill the gaps 
in the evidence.  However, RCTs may also not provide the required robust evidence. Many of 
the studies discussed above included RCTs with significant weaknesses.  A review of RCTs of 
pharmacist-led interventions to reduce unplanned admissions or readmissions also found a 
lack of effect of interventions[41]. 
19 
 
Humanistic outcomes:  Literature on humanistic outcomes is much sparser than the other two 
dimensions. The main humanistic outcomes that studies evaluate are patient satisfaction and 
health-related quality of life (HRQoL). The EAHP Statements do not mention hospital 
pharmacists’ responsibility for humanistic outcomes, although one statement (4.6) does refer 
to providing information to patients on the use of their medicines in terms they can understand.  
Pharmacy researchers have found limited or mixed evidence of the impact of pharmacists’ 
interventions on quality of life. Pickard et al.[20] in a 2006 overview of 36 studies (two from the 
UK), found limited evidence of the impact of a few CP interventions on short-term HRQoL. In 
their systematic review and meta-analysis, Holland and colleagues[37] could not find sufficient 
evidence to show that medication reviews for older people improved quality of life. Chisholm-
Burns et al.[34] also found that results for humanistic outcomes varied. Spinewine et al.[36] 
reviewed the literature on the role of pharmacists in optimising pharmacotherapy in older 
people. They also concluded that there is mixed evidence of the impact of pharmacists’ 
interventions on quality of life. There have therefore been calls for more sensitive outcome 
measures for pharmaceutical care services, including a medicines related quality of life 
tool[22]. 
 
Summary and suggestions for future work  
In order to demonstrate the benefit of CP, as for all healthcare interventions, evidence of its 
effectiveness in improving patient care and optimising resources is needed to justify and 
prioritise services. Currently, the quality of evidence supporting broad-based CP services is 
limited and outcomes have not been consistently demonstrated. There is little clarity on which 
specific CP roles, responsibilities and practices bring greatest benefit to patients, organisations 
or health service priorities, so it is unclear which should be prioritised or made universally 
available. Table 2 summarises those beneficial outcomes supported by systematic reviews.  
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Table 2. Benefits of clinical pharmacy interventions and services as indicated by the 
literature 
Outcome Benefits described in the literature 
Economic/Financial Savings on drug costs  
Cost-avoidance  
Clinical Improved quality of prescribing 
Reduced numbers of medications 
Resolution of drug-related problems 
Therapeutic goal attainment in specific conditions 
Humanistic Patient knowledge of their medicines 
Adherence  
 
See supplementary file 2 for a reading list of studies describing benefits of specific clinical 
pharmacy interventions. 
 
Research into the outcomes of UK hospital clinical pharmacy practice is scarce in the 
literature. This is possibly because CP is well-embedded in the UK National Health Service 
and therefore there is little motivation to demonstrate the benefits. However, the level of 
provision is not consistent across the health service because of a lack of evidence, aggravated 
by sub-optimal research.  Research is emerging from mainland Europe, where CP is currently 
less well established. It remains to be seen if published outcomes from Europe carry enough 
weight to influence policy on the development of CP.  
Economic evaluations of CP interventions need to be more methodologically robust and follow 
health economic guidelines more closely. However, the standard cost-benefit, cost-utility and 
cost-effectiveness analyses may not always be the most appropriate studies to conduct. 
These require benefits to be aggregated into a single outcome (for example, a monetary figure 
or a health-related quality of life measure), without allowing for the possibility that the impact of 
CP interventions may extend beyond this type of quantification. Cost-consequence analyses 
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(CCAs) do not try to put all the costs and benefits into the same units. CCAs allow for different 
types of benefits that cannot be combined. By disaggregating the consequences (outcomes), 
different weights can be applied to the various benefits, depending on one’s priorities[46]. The 
National Institute for Health and Care Excellence is now explicit about conducting cost-
consequence analyses (CCAs) of public health interventions, in recognition of the fact that 
CCAs can take into account the wider benefits of an intervention[47]. Given the complexity and 
multiple aims of CP services, CCAs offer many advantages over other economic 
evaluations[48]. Perhaps it is time that CCAs cease to be seen as a ‘lesser’ form of economic 
evaluation when it comes to CP interventions. 
 
As described above, CP practice research is often considered to have been poorly conducted 
(according to the accepted norms). The emphasis in the profession on mainly reporting and 
assessing evidence from quantitative studies is problematic and may in fact be weakening the 
case for CP. It is likely that studies have not measured those outcomes that CP interventions 
can influence.[21] RCTs and similar types of quantitative evidence reflect the positivist-realist 
epistemology which dominates clinical medicine[49,50]. Slade and Priebe[51], discussing the 
role of RCTs in mental health interventions, argue that the medical establishment’s insistence 
on dismissing all other types of evidence ignores the contributions from other methodologies in 
answering research questions. The same point could be made that CP interventions can often 
not be standardised or strictly defined. Some pharmacy researchers have urged the inclusion 
of a social science slant into pharmacy practice research[52]. In particular, the value of 
knowledge which arises from social sciences research, reflection, actions and practice 
experience[53] is rarely considered in the scholarly literature on CP practice.  Investigations 
into humanistic and clinical outcomes specifically, require different methodologies to 
understand the benefits that are valued by patients and other parties and to uncover any 
‘pharmacy-sensitive’ effects. For example, as there are various  factors that affect the rate of 
hospital admission, it is unlikely to be a sensitive outcome measure for CP[41]. More 
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humanistic outcomes urgently need to be demonstrated; qualitative methods are required to 
generate theories on what these might be.  
 
It is our view that a shared understanding of the aims and outcomes of CP is needed. The 
approach to achieving this should be inclusive and will integrate both institutional and patient-
centred goals.  Research into the outcomes of CP interventions will continue to be criticised for 
its lack of rigour until practitioners embrace alternative strategies. As well as cost-
consequence analyses, CP researchers should consider conducting robust qualitative and 
mixed-method (qualitative and quantitative) studies, utilising methodologies from evaluation, 
improvement and implementation science disciplines.  
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Supplementary FILE 1 .  Policy documents charting the history of the development of Hospital Clinical Pharmacy 
Author and Year Document Title Summary 
Noel Hall, 1970 Report of the Working Party on the 
Hospital Pharmaceutical Service   
Recommended pharmacists’ professional and scientific skills be used to ensure the safe, efficient and 
economical use of drugs.  Within a few years, hospital pharmacy services started to become ‘patient-
centred’ rather than ‘product-focused’. 
Clucas, K.  
Nuffield 
Foundation, 1986 
The Report of a Committee of lnquiry 
appointed by the Nuffield Foundation 
Defined CP as “a developing role… in which pharmaceutical skills are systematically applied to 
medicine usage both at the policy-making level and in the treatment of the individual patient”. 
Department of 
Health, 1988 
Health Services Management: the way 
forward for hospital pharmaceutical 
services, HC (88) 54  
Identified core elements of clinical pharmacy and endorsed hospital clinical pharmacy practice. Clinical 
Pharmacy becomes government policy. 
Crown, J. 1999 Review of prescribing, supply and 
administration of medicines. Final report 
Recommends the development of new categories of prescribers - ‘independent’ and ‘dependent’ (later 
‘supplementary’) from among non-doctor healthcare professionals.  As a direct result, since 2006, 
pharmacists have been able to qualify as independent prescribers, theoretically gaining much the same 
autonomous prescribing rights as doctors. 
Department of 
Health, 2000 
Pharmacy in the Future – Implementing 
the NHS Plan 
Clinical pharmacy services should do more ensure best use of medicines in hospitals. Hospital 
pharmacists should have their time freed up to focus on clinical care. Highlights one-stop dispensing, 
self-administration of medicines, prescribing in specialist areas, and prescribing take-home medicines 
as possible ways to make better use of pharmacists’ clinical skills. 
The Audit 
Commission, 2001 
A Spoonful of Sugar: Medicines 
Management in NHS Hospitals. Hospitals 
 
Defines medicines management in hospitals –“(it) encompasses the entire way that medicines are 
selected, procured, delivered, prescribed, administered and reviewed to optimise the contribution that 
medicines make to producing informed and desired outcomes of patient care”. Makes the case for the 
role of clinical pharmacy in improving care and reducing costs. 
Department of 
Health, 2003 
A Vision for Pharmacy in the New NHS Highlights the increasing integration of hospital pharmacists into clinical teams and the development of 
specialised clinical roles. 
Department of 
Health, 2003 
Medicines management in NHS Trusts: 
hospital medicines management 
framework 
Defines standards for the clinical and cost-effectiveness responsibilities of hospital pharmacy services. 
Commission for 
Healthcare Audit 
and Inspection, 
2007 
The best medicine: the management of 
medicines in acute and specialist trusts 
Highlights the role clinical pharmacists play in ensuring patient safety.  “The involvement of clinical 
pharmacy staff is clearly a service that benefits the safety of patients…” Uses the amount of clinical 
pharmacy time available as an indicator of effective medicines management. 
Royal 
Pharmaceutical 
Society, 2013 
Medicines Optimisation: Helping patients 
to make the most of medicines 
Consolidates the term ‘Medicines Optimisation’ and sets out the role of pharmacists and other health 
and social care professionals in ensuring individual patients get the best from their medicines. 
European 
Association of 
Hospital 
Pharmacy, 2014 
European Statements of Hospital 
Pharmacy 
Forty-four statements expressing commonly agreed objectives which every European health system 
should aim for in the delivery of hospital pharmacy services. 
Lord Carter of 
Coles, 2016 
Operational productivity and performance 
in English NHS acute hospitals: 
Unwarranted variations 
Recommends hospitals ensure 80% of pharmacist resource is spent on clinical / medicines 
optimisation services – “to deliver optimal use of medicines, make informed medicines choices, secure 
better value and drive better patient outcomes and 7-day health and care services”. 
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